![]() PDL BioPharma PDL BioPharma, Inc. engages in intellectual property asset management, and patent portfolio and related assets investment activities. | X4 Pharmaceuticals X4 Pharmaceuticals (formerly known as Arsanis) is a biopharmaceutical company that provides drug development services. | ![]() OSE Immunotherapeutics OSE Immunotherapeutics is a biotechnology company that focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. | ||
Founding Date | Founding Date 2015 | Founding Date 1986 | Founding Date 2010 | Founding Date 2012 |
Type | Type Private | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Hemel Hempstead, GB HQ | Locations Incline Village, US HQ | Locations Boston, US HQ Wien, AT | Locations Nantes, FR HQ Paris, FR |
Employees | Employees 965% decrease | Employees 10521% increase | Employees 1005% increase | Employees 52 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 282.1 m | Valuation ($) 83.9 m | Valuation ($) 239 m |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $54.8m (FY, 2019) | Revenue (est.) $6.5m (FY, 2025) | Revenue (est.) €69.9m (FY, 2024) |
Cost of goods | Cost of goods N/A | Cost of goods $53.6m (FY, 2019) | Cost of goods $5.8m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $1.1m (FY, 2019) | Gross profit $743k (FY, 2025) | Gross profit €83.4m (FY, 2024) |
Net income | Net income N/A | Net income ($70.7m) (FY, 2019) | Net income N/A | Net income €37.4m (FY, 2024) |
Funding | ||||
Total funding raised | Total funding raised $ 54.2m | Total funding raised N/A | Total funding raised $ 64.5m | Total funding raised $ 10.3m |

PDL BioPharma, Inc. engages in intellectual property asset management, and patent portfolio and related assets investment activities.
View companyX4 Pharmaceuticals (formerly known as Arsanis) is a biopharmaceutical company that provides drug development services.
View company
OSE Immunotherapeutics is a biotechnology company that focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases.
View company